IGS1 Stock Overview
IGC Pharma, Inc., a clinical stage biotechnology company, engages in developing cannabinoid-based formulations for treating diseases and conditions, including Alzheimer’s disease, dysmenorrhea, premenstrual syndrome, and chronic pain.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 1/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
IGC Pharma, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.42 |
52 Week High | US$0.69 |
52 Week Low | US$0.23 |
Beta | 1.77 |
1 Month Change | 14.67% |
3 Month Change | 62.31% |
1 Year Change | 45.52% |
3 Year Change | -66.67% |
5 Year Change | -63.21% |
Change since IPO | -96.07% |
Recent News & Updates
Recent updates
Shareholder Returns
IGS1 | DE Pharmaceuticals | DE Market | |
---|---|---|---|
7D | 1.0% | -2.2% | -1.4% |
1Y | 45.5% | -27.0% | 2.2% |
Return vs Industry: IGS1 exceeded the German Pharmaceuticals industry which returned -27% over the past year.
Return vs Market: IGS1 exceeded the German Market which returned 2.2% over the past year.
Price Volatility
IGS1 volatility | |
---|---|
IGS1 Average Weekly Movement | 20.2% |
Pharmaceuticals Industry Average Movement | 6.6% |
Market Average Movement | 4.9% |
10% most volatile stocks in DE Market | 10.2% |
10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: IGS1's share price has been volatile over the past 3 months.
Volatility Over Time: IGS1's weekly volatility has increased from 15% to 20% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2005 | 61 | Ram Mukunda | igcpharma.com |
IGC Pharma, Inc., a clinical stage biotechnology company, engages in developing cannabinoid-based formulations for treating diseases and conditions, including Alzheimer’s disease, dysmenorrhea, premenstrual syndrome, and chronic pain. The company has two investigational drug assets targeting Alzheimer’s disease comprising IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer’s; and TGR-63 that is in pre-clinical development. It also markets Holief, a wellness brand that targets women experiencing premenstrual syndrome and menstrual cramps.
IGC Pharma, Inc. Fundamentals Summary
IGS1 fundamental statistics | |
---|---|
Market cap | €33.56m |
Earnings (TTM) | -€13.26m |
Revenue (TTM) | €1.14m |
29.4x
P/S Ratio-2.5x
P/E RatioIs IGS1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
IGS1 income statement (TTM) | |
---|---|
Revenue | US$1.22m |
Cost of Revenue | US$591.00k |
Gross Profit | US$625.00k |
Other Expenses | US$14.77m |
Earnings | -US$14.14m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.21 |
Gross Margin | 51.40% |
Net Profit Margin | -1,163.24% |
Debt/Equity Ratio | 1.6% |
How did IGS1 perform over the long term?
See historical performance and comparison